Article
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.
Cancer research - 15 Jun 2015
Eberlein Catherine A, Stetson Daniel, Markovets Aleksandra A, Al-Kadhimi Katherine J, Lai Zhongwu, Fisher Paul R, Meador Catherine B, Spitzler Paula, Ichihara Eiki, Ross Sarah J, Ahdesmaki Miika J, Ahmed Ambar, Ratcliffe Laura E, O'Brien Elizabeth L Christey, Barnes Claire H, Brown Henry, Smith Paul D, Dry Jonathan R, Beran Garry, Thress Kenneth S, Dougherty Brian, Pao William, Cross Darren A E
Abstract excerpt
Resistance to targeted EGFR inhibitors is likely to develop in EGFR-mutant lung cancers. Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies. We describe the detection of heterogeneous mechanisms of resistance within populations of EGFR-mutant cells (PC9 and/or NCI-H1975) with acquired resistance to current and newly developed...
Topics
- Acrylamides
- Aniline Compounds
- Animals
- Antineoplastic Combined Chemotherapy Protocols
- Benzimidazoles
- Cell Line, Tumor
- Drug Screening Assays, Antitumor
- ErbB Receptors